Live tape
Top 8, mentions 7d7,412NVDA1,293 mentions▲ +0.09GOOGL1,128 mentions▲ +0.04AVGO1,031 mentions▲ +0.05NKE1,013 mentions+0.02LULU956 mentions▲ +0.03TSLA894 mentions▲ +0.06META581 mentions▲ +0.05MSFT516 mentions▲ +0.06

Equity · Healthcare

INCY

Incyte Corporation · NasdaqGS

$117 0.00% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 26 sessions
$120 $90 10 Jun 17 Jul

The line runs $105 on 10 June through $117 on 17 July, on a scale from $90 to $120. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of INCY over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $105 on 10 June 2026 through $117 on 17 July 2026.

Market cap $23.4B
P/E (TTM) 18.2
52-week range $67.40 – $119
Avg volume 349.6K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

INCY insider trades

SEC Form 4 · last 90 days · newest reported trade 19 Aug 2026
Open-market buys 0
Open-market sells 10
Net sold $15.40M
Non-trade filings 28
Date Insider Type Shares Value
19 Aug 2026 CAGNONI PABLO J President, Global Head of R&D Sell 10,801 $1.36M
12 Aug 2026 CAGNONI PABLO J President, Global Head of R&D Sell 10,803 $1.30M
05 Aug 2026 CAGNONI PABLO J President, Global Head of R&D Sell 10,640 $1.31M
05 Aug 2026 Mayes Patrick A EVP & Chief Scientific Officer Sell 2,207 $274K
03 Aug 2026 Mayes Patrick A EVP & Chief Scientific Officer Sell 6,055 $729K
31 Jul 2026 CAGNONI PABLO J President, Global Head of R&D Sell 15,888 $1.90M
31 Jul 2026 Mayes Patrick A EVP & Chief Scientific Officer Sell 41,899 $5.01M
16 Jul 2026 Stein Steven H CMO & Head of Late-Stage Dev. Sell 1,877 $215K
16 Jul 2026 Issa Mohamed Khairie EVP, Head of U.S. Commercial Sell 1,093 $126K
15 Jul 2026 Stein Steven H CMO & Head of Late-Stage Dev. Sell 28,237 $3.19M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
25 Aug 2026 Basi Ramitpal K EVP, Human Resources Tax withheld 504 $65K
05 Aug 2026 Mayes Patrick A EVP & Chief Scientific Officer Option exercise 2,207 $235K
03 Aug 2026 Mayes Patrick A EVP & Chief Scientific Officer Option exercise 6,055 $638K
31 Jul 2026 Mayes Patrick A EVP & Chief Scientific Officer Option exercise 37,089 $2.73M
16 Jul 2026 Basi Ramitpal K EVP, Human Resources Award 4,991
16 Jul 2026 CAGNONI PABLO J President, Global Head of R&D Award 13,403
16 Jul 2026 Gardner David H EVP, Chief Strategy Officer Award 7,395
16 Jul 2026 Hoffman Richard A. EVP & General Counsel Award 7,395
16 Jul 2026 Meury William Chief Executive Officer Award 26,807
16 Jul 2026 Stein Steven H CMO & Head of Late-Stage Dev. Award 9,798
16 Jul 2026 Tray Thomas Principal Accounting Officer Award 2,834
16 Jul 2026 Issa Mohamed Khairie EVP, Head of U.S. Commercial Award 7,857

Showing the 12 most recent of 28 compensation filings in this window. The figures above count all of them.

INCY reported financials

SEC EDGAR XBRL

INCY reported revenue of $5.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.3B.

Figure Reported Period
Revenue $5.1B 31 Dec 2025 fiscal year
Net income $1.3B 31 Dec 2025 fiscal year
Diluted EPS $6.41 31 Dec 2025 fiscal year
Total assets $7.3B 31 Mar 2026 at period end
Total equity $5.6B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

INCY earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $1.47 —
31 Dec 2025 FY 2025 $6.41 —
30 Sep 2025 Q3 2025 $2.11 —
30 Jun 2025 Q2 2025 $2.04 —
31 Mar 2025 Q1 2025 $0.80 —
31 Dec 2024 FY 2024 $0.15 —
30 Sep 2024 Q3 2024 $0.54 —
30 Jun 2024 Q2 2024 $-2.04 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

INCY institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a INCY position for the quarter ended 30 Jun 2026 — a combined $5.0B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) +0.1% shares 30,762,330 $3.5B
AQR Capital Management Held (±25%) −8.4% shares 5,320,901 $603.2M
Renaissance Technologies Held (±25%) −3.8% shares 3,512,132 $398.1M
Two Sigma Investments Added +381.7% shares 2,003,559 $227.1M
Marshall Wace Held (±25%) +4.5% shares 1,310,154 $148.5M
Man Group Held (±25%) +2.4% shares 952,941 $108.0M
Bridgewater Associates Added +29.1% shares 168,253 $19.1M
Citadel Advisors Added +191.2% shares 143,509 $16.3M
Fisher Asset Management Held (±25%) +21.5% shares 137,018 $15.5M
Millennium Management Trimmed −52.1% shares 82,812 $9.4M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

INCY fails-to-deliver

SEC CNS data

On 11 Aug 2026, 951 shares of INCY failed to deliver (about $116K).

Settlement date Shares failed Notional % of shares out
11 Aug 2026 951 $116K <0.001%
04 Aug 2026 1,036 $123K 0.001%
03 Aug 2026 1,890 $226K 0.001%
31 Jul 2026 11,788 $1.4M 0.006%

Source: SEC fails-to-deliver (CNS) data